⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery

Official Title: Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study

Study ID: NCT00104936

Study Description

Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving radiation therapy or radiosurgery after surgery may kill any remaining tumor cells. It is not yet known whether radiation therapy or radiosurgery is more effective than observation alone in treating benign meningioma. PURPOSE: This randomized phase III trial is studying radiation therapy or radiosurgery to see how well they work compared to observation alone in treating patients with newly diagnosed, benign meningioma that has been partially removed by surgery.

Detailed Description: OBJECTIVES: Primary * Compare progression-free survival of patients with newly diagnosed, incompletely resected, benign intracranial grade I meningioma treated with adjuvant conventional fractionated radiotherapy or radiosurgery vs observation only. Secondary * Compare the quality of life of patients treated with these regimens. * Compare overall survival of patients treated with these regimens. * Compare the incidence of a second surgery in patients treated with these regimens. * Compare the incidence of acute and long-term neurotoxicity in patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to post-surgery MRI staging (3 vs 4 vs 5), skull base location (yes vs no), age (\< 60 vs ≥ 60), and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo observation only. * Arm II: Within 4-7 months after surgery, patients undergo conventional fractionated radiotherapy once daily, 5 days a week for 6 weeks OR a single treatment of high-dose radiosurgery in the absence of unacceptable toxicity. Quality of life is assessed at baseline, at 6 months after randomization, and then annually thereafter. After completion of study treatment, patients are followed at 3 and 6 months after randomization and then annually thereafter. PROJECTED ACCRUAL: A total of 478 patients (239 per treatment arm) will be accrued for this study within 3-4 years.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, , Germany

Radiotherapeutisch Instituut-(Riso), Deventer, , Netherlands

University Medical Center Rotterdam at Erasmus Medical Center, Rotterdam, , Netherlands

Hopital Cantonal Universitaire de Geneve, Geneva, , Switzerland

Contact Details

Name: John G. Wolbers, MD, PhD

Affiliation: University Medical Center Rotterdam at Erasmus Medical Center

Role: STUDY_CHAIR

Name: Raymond Miralbell, MD

Affiliation: Hopital Cantonal Universitaire de Geneve

Role: STUDY_CHAIR

Name: Rolando F. Del Maestro, MD, PhD

Affiliation: Montreal Neurological Institute and Hospital

Role: STUDY_CHAIR

Name: Luis Souhami, MD

Affiliation: McGill Cancer Centre at McGill University

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: